ID
33107
Descrizione
Study ID: 104021 Clinical Study ID: 104021 Study Title: A phase III, partially blind, randomized study to evaluate the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ Tritanrix™-HepB and GSK Biologicals Kft’s DTPw-HBV vaccines as compared to concomitant administration of Commonwealth Serum Laboratory’s (CSL’s) DTPw (Triple Antigen™) and GSK Biologicals’ HBV (Engerix™-B), when co-administered with GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine, to healthy infants at 3, 4½ and 6 months of age, after a birth dose of hepatitis B vaccine. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00158756 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: Hepatitis B Vaccine, Recombinant Trade Name: Engerix B Study Indication: Hepatitis B
Keywords
versioni (1)
- 28/11/18 28/11/18 -
Titolare del copyright
GSK group of companies
Caricato su
28 novembre 2018
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Immunogenicity of co-administration of Tritanrix™-HepB and DTPw-HBV vaccines or Triple Antigen™ and Engerix™-B with HRV vaccine to infants (3, 4½ and 6 month) - 104021
Contraindications to Subsequent Vaccination
- StudyEvent: ODM
Descrizione
DTPw vaccines
Descrizione
GSK Biologicals' RotarixTM vaccine or its placebo
Descrizione
Local registered OPV
Descrizione
Relative Contraindications
Descrizione
If any one of these AEs occurs at the time scheduled for vaccination, the subject may be vaccinated at a later date, within the time window specified in the protocol, or withdrawn at the discretion of the investigator. The subject must be followed until resolution of the event, as with any AE.
Tipo di dati
text
Descrizione
DTPw vaccines
Descrizione
GSK Biologicals' RotarixTM or its placebo
Descrizione
Precautions for DTPw vaccines
Descrizione
If any of the following events occur in temporal relation to receipt of the study vaccines, the decision to give subsequent doses of vaccine containing the pertussis component should be carefully considered. The following event were previously considered contraindications and are now considered precautions by the Advisory Committee on Immunization Practices (ACIP)
Tipo di dati
text
Descrizione
DTPw-HBV vaccines should under no circumstances be administered intravenously
Similar models
Contraindications to Subsequent Vaccination
- StudyEvent: ODM